Neuraxis (NRXS) Assets Average (2023 - 2025)
Neuraxis (NRXS) posted Assets Average of $6.1 million for Q4 2025, down 5.32% sequentially from $6.4 million in Q3 2025, and up 106.42% YoY from $3.0 million in Q4 2024.
Neuraxis (NRXS) Assets Average (2023 - 2025) Analysis & Trends
Neuraxis has reported Assets Average for 3 years, with the latest figure at $6.1 million in Q4 2025.
- Quarterly Assets Average rose 106.42% year-over-year to $6.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.1 million (up 106.42% YoY) and the FY2025 annual result came in at $5.6 million, up 111.91% from the prior year.
- Assets Average declined to $6.1 million in Q4 2025 per NRXS's latest filing, from $6.4 million in the prior quarter.
- Over five years, Assets Average peaked at $6.4 million in Q3 2025 and troughed at $727613.5 in Q1 2024.
- A 3-year average of $3.1 million and a median of $2.4 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2024 and 2025: Assets Average soared 36.06% in 2024, then surged 435.13% in 2025.
- Over 3 years, Assets Average stood at $872708.0 in 2023, then surged by 238.08% to $3.0 million in 2024, then jumped by 106.42% to $6.1 million in 2025.
- According to Business Quant data, Assets Average over the past three periods registered $6.1 million, $6.4 million, and $5.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.92 Bn | 53.78 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.70 Bn | 28.39 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 27.99 Bn | 9.60 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 19.82 Bn |
| 10 | Neuraxis | 74.90 Mn | 66.58 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.09 Mn |
| Sep 30, 2025 | 6.43 Mn |
| Jun 30, 2025 | 5.06 Mn |
| Mar 31, 2025 | 3.89 Mn |
| Dec 31, 2024 | 2.95 Mn |
| Sep 30, 2024 | 1.89 Mn |
| Jun 30, 2024 | 1.79 Mn |
| Mar 31, 2024 | 727,613.50 |
| Dec 31, 2023 | 872,708.00 |
| Sep 30, 2023 | 1.39 Mn |